Lyophilization Services for Biopharmaceuticals Market Report 2026

The lyophilization services for biopharmaceuticals market size has grown rapidly in recent years. It will grow from $2 billion in 2025 to $2.21 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to growth in biopharmaceutical production, rising demand for long term drug stability, expansion of clinical research activities, increasing reliance on outsourced pharmaceutical services, development of lyophilization infrastructure.

The lyophilization services for biopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $3.35 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to increasing biologics and vaccine development, rising focus on temperature sensitive pharmaceuticals, growing adoption of contract manufacturing services, expansion of pharmaceutical R&D investments, stronger emphasis on global medicine distribution stability. Major trends in the forecast period include increasing demand for stability enhancement of biopharmaceuticals, rising adoption of freeze drying in drug development, growing emphasis on extended shelf life solutions, expansion of contract lyophilization service offerings, increasing focus on high quality preservation techniques.

The increasing demand for biologics is anticipated to drive the growth of the lyophilization services for the biopharmaceuticals market in the coming years. Biologics are therapeutic products that originate from living organisms or contain components derived from living systems. Lyophilization services are widely applied to biologics within the pharmaceutical and biopharmaceutical sectors. This process supports the preservation of biologic stability by reducing the risk of denaturation or degradation. It also aids in enhancing stability and maintaining overall product integrity. For example, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, as of January 2022, the United States had 33 FDA-approved biosimilar products, with 21 available commercially. By 2023, this figure rose to 40 FDA-approved biosimilars, of which 25 were available on the market. Therefore, the rising demand for biologics is driving the lyophilization services for the biopharmaceuticals market.

Leading companies in the lyophilization services for biopharmaceuticals market are developing technologies such as modular design to improve flexibility and scalability in production processes, enhance equipment utilization efficiency, and facilitate faster adaptation to evolving manufacturing demands. Modular design involves breaking down a system into smaller, self-contained units or modules, which allows for flexibility, easy customization, and efficient reconfiguration or replacement of components without disrupting the entire system. For example, in June 2024, Syntegon Technology, a Germany-based machine industry company, introduced the Modular Bioprocessing Platform (MBP). This platform is modular in nature, allowing customization for various applications, including microbial and mammalian cell cultures, proteins, peptides, oligonucleotides, plasmid DNA, and recombinant vaccines. This design enables biopharmaceutical manufacturers to quickly adjust to changing production requirements while maintaining quality.

In June 2024, Bora Pharmaceuticals Co. Ltd., a pharmaceutical company based in Taiwan, acquired Emergent BioSolutions Inc. for an undisclosed amount. This acquisition is intended to enhance Bora Pharmaceuticals' product portfolio, expand its market presence, and strengthen its research and development capabilities. Emergent BioSolutions Inc. is a US-based company that produces a variety of biopharmaceutical products.

Major companies operating in the lyophilization services for biopharmaceuticals market report are Strides Pharma Science Limited, Baxter International Inc., Catalent Pharma Solutions Inc, Vetter Pharma International GmbH, Curia Global Inc., Corden Pharma GmbH, Lyophilization Services of New England Inc., Jubilant HollisterStier LLC, Dalton Pharma Services, IDT Biologika GmbH, Ardena Group, Axcellerate Pharma LLC, Symbiosis Pharmaceutical Services, Biofortuna Limited, Rentschler Fill Solutions GmbH, Lyophilization Technology Inc., Pyramid Laboratories Inc, AB BioTechnologies Inc., Biopharma Process Systems, Labyrinth Biopharma LLC, Gilyos GmbH, ProJect Pharmaceutics GmbH, BioZed Engineering Pvt. Ltd., Berkshire Sterile Manufacturing, Millrock Technology Inc.

North America was the largest region in the lyophilization services for biopharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyophilization services for biopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lyophilization services for biopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lyophilization services for biopharmaceuticals market includes revenues earned by entities by providing scale-up and manufacturing, process optimization services, packaging solutions, stability studies, regulatory support, consulting, and technical support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.